{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.0","upperLimit":"73.6","value":"63.7"},{"groupId":"OG001","lowerLimit":"56.6","upperLimit":"96.2","value":"82.4"},{"groupId":"OG002","lowerLimit":"68.1","upperLimit":"87.5","value":"78.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"76"}],"units":"Participants"}],"title":"KIF5B"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.5","upperLimit":"85.1","value":"68.0"},{"groupId":"OG001","lowerLimit":"19.4","upperLimit":"99.4","value":"75.0"},{"groupId":"OG002","lowerLimit":"60.4","upperLimit":"96.6","value":"84.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"CCDC6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"100","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"NCOA4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.2","upperLimit":"74.9","value":"46.2"},{"comment":"The 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG002","lowerLimit":"30.8","upperLimit":"89.1","value":"63.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"106"}],"units":"Participants"}],"description":"Oncogenic RET rearrangements have been identified in 1%-2% of NSCLC. These rearrangements typically produce chimeric transcripts that encode a fusion protein consisting of the RET kinase domain coupled to a protein with a dimerization domain (e.g., Kinesin family member 5B (KIF5B), coiled-coil domain containing 6 (CCDC6), nuclear receptor coactivator 4 (NCOA4)). RET genotypes were determined by local testing and/or central analysis of circulating tumor deoxyribonucleic acid (ctDNA). ORR was assessed in participants having specific RET rearrangements. ORR was defined as the percentage of participants with a confirmed CR or PR for at least 2 assessments with at least 28 days apart and no PD in between. CR, PR, and PD were defined per RECIST as outlined in the description for OM 3.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who had RET-fusion positive NSCLC previously treated with platinum-based chemotherapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG000","title":"RET- Fusion Positive NSCLC With Prior Platinum Treatment"},{"description":"Participants who had RET-fusion positive NSCLC previously treated with non-platinum or systemic therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG001","title":"RET-fusion Positive NSCLC With Non-platinum Systemic Treatment"},{"description":"Participants who had RET-fusion positive NSCLC not previously treated with systemic or platinum-based chemotherapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG002","title":"RET-fusion Positive NSCLC With No Prior Systemic or Platinum Treatment"}],"paramType":"NUMBER","populationDescription":"RET-altered measurable disease population included participants in the efficacy population who have measurable (target) disease per RECIST v1.1, at baseline according to BICR and sufficient evidence of a RET alteration. As prespecified in the SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. Number analyzed is the number of participants with the specified mutation.","reportingStatus":"POSTED","timeFrame":"Up to approximately 79.8 months","title":"Phase 1 and Phase 2: ORR in RET-fusion Positive NSCLC Participants With Specific RET Gene Status","type":"SECONDARY","unitOfMeasure":"percentage of participants"}